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CObjectives: To explore the extent of and barriers to the use of eco-
nomic evaluation in compiling the Jordan Rational Drug List in the
health care system of Jordan. Methods: The research reported in this
article involved a case study of the Jordan Rational Drug List. Data
collection methods included semi-structured interviews with decision
makers and analysis of secondary documentary sources. The case
studywas supplemented by additional interviewswith a small number
of Jordanian academics involved in the production of economic
evaluation. Results: The research found that there was no formal re-
quirement for cost-effectiveness information submitted as part of the
decision-making process for the inclusion of new technologies on the
Jordan Rational Drug List. Both decision makers and academics sug-
gested that economic evidence was not influential in formulary deci-
sions. This is unusual for national formulary bodies. The study identi-
fied a number of barriers that prevent substantive and routine use of O
910, J
al So
ttp://dx.doi.org/10.1016/j.jval.2012.04.006conomic evaluation. While some of these echo findings of previous
tudies, others—notably the extent to which the sectional interests of
linical groups and commercial (pharmaceutical) industry exert undue
nfluence over decision making—more obviously result from the spe-
ific Jordanian context. Conclusions: Economic evaluation was not
ound to be influential in the Jordan Rational Drug List. Recommenda-
ions for improvement include enhancing capacity in relation to gen-
rating, accessing, and/or applying health economic analysis to prior-
ty setting decisions. There is a further need to incentivize the use of
conomic evaluation, and this requires that organizational and struc-
ural impediments be removed.
eywords: decision making, economic evaluation, Jordan, priority
etting, rationing.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
In these times of heightened fiscal constraint, the need for priority
setting in health care is expected to gain more attention [1].
Expenditure on health care continues to decrease, especially in
low- and middle-income countries, raising concerns over the in-
efficient allocation of health care resources [2]. As health care de-
mand continues to outstrip supply, there is a growing interest in
using economic evaluation to help solve the problems of resource
scarcity and this can be seen as part of a wider concern to adopt
“evidence-based policy” and to achieve “best value for money”
[3,4]. The expected gains from such an approach are cast in terms
of improved efficiency, transparency, and accountability. Practical
experience, however, indicates significant implementation chal-
lenges and a limited impact on actual resource allocation [5–7].
Considering the large financial input required to conduct eco-
nomic evaluation research [3], assessment of the readiness of
health system institutions is important in deciding the feasibility
of such investment. The study reported in this article adds to a
growing body of empirical research into the use of economic eval-
uation in priority setting. Drawing on conceptual frameworks and
research experiences developed in previous studies, a qualitative
methodology is employed to explore knowledge, attitudes, and
experiences in relation to economic evaluation among decision
makers involved in the Jordan Rational Drug List (JRDL). In so do-
* Address correspondence to: Rania Lafi, PO Box 1904, Amman–11
E-mail: rania.lafi@gmail.com.
098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.ing, the research findings offer an assessment of the current ca-
pacity of this function to produce, access, and apply economic
evidence.
Economic evaluation in health care
Economic evaluation of health care technologies comprises the
comparison of costs and consequences of interventions and is
mainly concerned with attaining higher efficiency through the
maximization of health outcomes from available resources
[8,9]. It is therefore a potentially key methodology for improving
health care priority setting, which is defined here as the process
for making decisions over the allocation of population health
care resources. Priority setting within publicly funded health
systems is consistently described as a complex process that
involves difficult decisions. Setting priorities in an ad hoc, his-
tory-based, and intuitivemanner is reportedly the norm inmost
developing countries [10]. In response, the use of economic
evaluation, and the broader concept of health technology as-
sessment, has been strongly advocated by international organi-
zations such as the World Bank and the World Health organiza-
tion especially in settings in which health care budgets are
severely constrained [11]. Experience suggests, however, that
employing research evidence and following a rational approach
to reach decisions are rarely evident in practice and that al-
though economic evaluation sometimes informs decision pro-
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[12]. A more realistic appraisal of the decision-making process
suggests a wider set of interests and considerations that deci-
sion makers have to balance [3]. Gaining a fuller understanding
f decision making in priority setting from the perspective of
ecision makers requires empirical research that aims to iden-
ify contextual factors, key actors, and main interests influenc-
ng this process. Such studies provide opportunities for policy
earning for the design and implementation of policy interven-
ions on the basis of evidence-based strategies [13].
There are an increasing number of studies that aim to un-
cover the impact of economic evaluation and factors associated
with its use in decision making. A framework introduced by
Williams and Bryan [9] categorizes barriers to the use of eco-
nomic evaluation into “accessibility” and “acceptability” fac-
tors. Accessibility factors refer to “the availability of relevant
research in a timely manner, the clarity of its presentation and
the extent to which it can be understood by policymakers” [9].
Acceptability factors refer to the perceived appropriateness of
economic evaluation as a solution to the problems posed by
resource scarcity. Issues related to decision-making context
such as closed budgets, organizational constraints, and ethical
and political factors, in addition to methodological concerns,
are consistently cited barriers that militate against the accept-
ability of economic evidence [6].
The Jordan rational drug list
In Jordan, the health sector contains a mix of public and private
providers. The public sector provides health insurance for 56%
of the population under four schemes: the Royal Medical Ser-
vices; the Ministry of Health–administered civil insurance; and
two university hospitals: Jordan University Hospital and King
Abdullah University Hospital. Health care expenditure accounts
for 10% of the gross domestic product, yet nearly 30% of the
population has no formal insurance [14]. To address this prob-
lem, in the face of growing pressures on the health care budget,
a plan for a universal health care coverage is in progress and is
expected to be implemented by the end of 2012 [14]. As a result,
the government has introduced a number of initiatives to ad-
dress the need for cost-containment and improve efficiency es-
pecially in areas of excessive expenditure. In particular, phar-
maceuticals—which absorb 3% of the gross domestic product
and 30% of health care expenditure—were prioritized for these
measures [15].
A rational drug list—the JRDL—has been created as a vehicle
for addressing these expenditure deficits in pharmaceuticals,
Table 1 – Jordan rational drug list.
The JRDL is a positive listing of drugs that are deemed to be cost-e
inclusion criteria for new medicines and for the removal of existin
of the population.
The selection criteria of the JRDL are based on internationally re
published sources including the following: The Selection and Use
2002; and WHO Model List of Essential Medicines, 2002.
Inclusion on the JRDL is reportedly based on the following evidenc
● Relevance to disease area in question.
● Efficacy and safety based on adequate pharmacological studies.
● Quality: Drugs must meet quality control standards as set out by
● Cost of treatment regimen.
● Drug formulation.
The JRDL is available from the Jordan Food and Drug Administrati
committee comprising physicians and pharmacists provide techn
However, a weakness of the process relates to the fact that there i
serving on the committee. Furthermore, the selection criterion for
JRDL, Jordan Rational Drug List.its purpose being to help the government purchase clinical andcost-effective medicines that match the health needs of its pop-
ulation [15,16]. The JRDL is revised and updated annually (or
whenever necessary) by the National Pharmacy and Therapeu-
tic Committee, which is formed from chairpersons of the Jordan
National Drug Formulary. Technical committees provide advice
on the revision and update of the JRDL, and these committees
have a representative from the four main public sector health
care provider agencies, the Jordan Food and Drug Administra-
tion, and the Joint Procurement Department. The list is used to
update the Jordan National Drug Formulary, which, in turn, is
used to guide the procurement of pharmaceuticals in the public
sector through the Joint Procurement Department [15]. There
are 17 national drug formulary (Jordan National Drug Formu-
lary) technical committees in Jordan, and these are intended to
cover all relevant medical fields. The members are nominated
by their respective public sector agencies and officially ap-
pointed by the minister of health [15].
Given the avowed aim of containing cost and improving ef-
ficiency, the JRDL is arguably a key vehicle for the application of
the principles and methodologies of economic evaluation. In
keeping with national formulary arrangements elsewhere, the
process of inclusion and exclusion on the JRDL could therefore
incorporate some form of cost-effectiveness “hurdle” or
“threshold” [17]. The selection criteria for making decisions
about what is included and/or deleted from the list are outlined
in Table 1. While there is some reference made to costs, there is
no formal reference to cost-effectiveness. However, concerns
have been raised over the ambiguity of a number of the listed
criteria and initiatives have been employed with the aim of
improving the transparency and accountability of decision-
making processes including economic evaluation to guide deci-
sion making [18,19]. For example, one recent pilot project
sought to design an evidence-based clinical guideline for cost-
effective pharmacological treatment of essential hypertension
(a high-priority disease area). The project involved consultation
and training provided by UK’s National Institute for Health and
Clinical Excellence and was funded by the World Bank [19].
However, there has been little by way of investigation into the
feasibility and appropriateness of these developments within
the Jordanian context in particular, or within developing coun-
tries more widely [20]. This is despite widespread interest in
equivalent national decision making in developed countries
such as the United Kingdom and Israel [21,22]. This study there-
fore seeks to address this gap via a case study of the JRDL as an
example of national-level priority setting in a developing
ve and meet the health needs of the population, and as such the
dicines from the list are based on both the cost and health needs
zed criteria obtained from several World Health Organization
ential Medicines, 2002; Promoting Rational Use of Medicines,
RDL.
eb site (www.jdfa.jo/RDL2/annex/Annex.htm). A selection
pport and advice on the revision and update of the JRDL.
ritten guidance in relation to the conflict of interest of those
mittee members is not made publicly available [16].ffecti
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As a newly formed process, relatively little is currently known
about the JRDL. Therefore, the study approach adopted was in-
tended to be exploratory [23]. Semi-structured interviews were
the main data collection method, supported by documentary
analysis of secondary sources produced by governmental and
nongovernmental organizations. The interviews focused on
current capacity for producing and using economic evaluation,
as well as exploring the decision-making environment in rela-
tion to the allocation of health care resources and the role of
economic evaluation in this process. The sample of potential
participants was purposively selected to cover two groups:
those who produce economic evidence such as academics and
those charged with carrying out priority setting decisions. This
latter group included members of drug selection committees at
a national level and senior managers in the public sector agen-
cies represented. With regard to the former group, the research
team sought to recruit informants who had been directly in-
volved in recent attempts to introduce economic evaluation in
resource allocation in Jordan, because they were assumed to
have key perspectives and be rich sources of information. The
selected sample was also intended to be as diverse as possible to
reflect a broader range of perspectives. Table 2 summarizes the
number of interviewees and their roles and positions. Invita-
tions were sent to potential participants via e-mail, followed by
telephone calls. All respondents were sent an advance copy of
the interview schedule.
Two interview schedules were developed, one for each group
of participants, drawing on those developed in a similar study
by Williams et al. [6]. Schedules were modified to reflect the
Jordanian research setting. Interview questions sought to inves-
tigate the knowledge, experience, and attitudes of interviewees
by predominantly using open-ended questions. Research was
carried out in the period between June and August 2010, with
interviews conducted by telephone in Arabic and audio-re-
corded with the consent of interviewees after an assurance of
confidentiality was given. Of the 35 selected informants, only 10
(28.6% response rate) consented to participate. Themain reason
given for nonparticipation was that respondents were too busy
to devote time to conducting an interview. The response rate
may also be indicative of the small number of people involved in
economic evaluation within Jordanian health care. Although
this partial coverage affects the extent of data saturation that
can be achieved, as an exploratory study it constitutes sufficient
data for emergent themes to be identified [24].
The duration of interviews ranged from 30 to 60 minutes. All
interviews were transcribed verbatim and translated into Eng-
lish immediately after each interview. Thematic analysis was
undertaken with the aim of “identifying, analyzing and report-
ing patterns (themes) within data” [24]. Given the exploratory
Table 2 – Roles and positions of interviewees.
Role Position No.
interviewed
Producers
(academics)
Economist 1
Health economist 1
Pharmacoeconomist 1
Potential users
(decision
makers)
Decision maker (public sector,
national level)
3
Clinician (public sector) 2
Clinician (private sector) 1
Pharmacologist (public sector,
hospital level)
1nature of the study, themes were identified inductively andwritten up so as to provide a rich description of this informa-
tion. These were then analyzed against the research questions
and in the light of previous research on this topic.
Results
This section presents the main themes identified in the inter-
views.
Constraints on producing economic evaluation
Academics cited threemain barriers that constrain the ability of
Jordanian research bodies to produce appropriate economic
evaluation data: 1) lack of skilled researchers, 2) unavailable or
fragmented data, and 3) shortage in funding. These three barri-
ers confirm those identified in other studies conducted in de-
veloping countries [7,25,26]. As is the case in many developing
countries, Jordan faces shortages in trained health economics
researchers and this was apparently reflected in the difficulty
we experienced when seeking to recruit participants to this
study. Searching university Web sites to identify specialists in
health economics and pharmacoeconomics resulted in only
seven potential participants. Two of the seven academics ap-
proached declined to participate on the grounds that they did
not consider the topic to be relevant to their research. At the
time of this study, there were only three identified pharmaco-
economists working in Jordanian universities. The interview-
ees’ cited this relatively low base of expertise as a key problem
for health system research in general and for economic evalu-
ation in particular.
Respondents also identified insufficient data as an important
constraint in conducting economic evaluations. Databases for ep-
idemiological data, clinical practice, and administration registries
were considered to be incomplete and fragmented across public
sector organizations.
I can speak from my own experience. In one study we conducted
the research team had to go door to door to gather patients’ data
because the records were incomplete or not available. (Academic
Interviewee 2)
This problem has also been noted in other reports and brought to
the attention of policymakers [19]. Recently, the Jordanian govern-
ment has initiated a project for an electronic health network to
integrate data from all public sector organizations [27], a step that
is expected to help in solving the problem of availability of data.
Respondents indicated international organizations as the main
source of funding for health research in Jordan and theMinistry of
Health has recently identified a list of top-priority topics for health
research [28]. This document, however, does not provide details
on the budget assigned for each topic, and respondents considered
there to be a shortage of public resources for conducting health
economic studies, with most studies funded by private organiza-
tions. They also reported that securing funds for research projects
from international organizations has become more difficult as a
result of the recent economic crisis.
Funding is a huge problem. The government’s spending on research
is very low and we are having less financial support from interna-
tional organizations these days because of the economic situation.
(Academic Interviewee 3).
Knowledge and understanding
Consistent with previous studies [25,26], decisionmakers had lim-
ited knowledge and understanding of economic evaluation meth-
odologies, applications, and limitations. Although decision mak-
ers varied in their estimation of their own knowledge, those who
assumed a capability to interpret this information declared that
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confuse economic evaluation with other concepts such as cost
analysis.
It’s not that difficult to understand. Everything is clear; storage
costs, treatment delivery cost . . . I think anyone in the health
care field can understand this information. (Decision Maker In-
terviewee 3)
In contrast, decisionmakerswhohadundertaken some training in
economic evaluation or had attended workshops on this subject
expressed concerns about their poor understanding and levels of
expertise:
I can’t say I fully understand this information. To be frank, I don’t,
and I have been to workshops and training courses. And I don’t
think many people do. But we use simple terms; for example, what
is the add-on of this drug that can justify the cost difference? (De-
cision Maker Interviewee 6)
All the decision makers interviewed expressed their interest in
attending training courses or workshops on economic evalua-
tion, although they were not able to specify the type of training
they considered would be most helpful. Clearly, this may partly
reflect selection bias because the majority of those decision
makers approached had declined to participate in the study.
Academic interviewees strongly recommended teaching health
economics as part of the medical curriculum, because most se-
nior officials and hospital managers in Jordan are clinicians.
Pharmacoeconomics is currently taught in only one university
as a three-credit course as part of the clinical pharmacy curric-
ulum, and economic evaluation is not currently taught in any of
the country’s medical schools. Some universities teach courses
in health economics as part of other programs such as econom-
ics and health management. This dearth of educational oppor-
tunities is not unique to Jordan, and inmost countries economic
evaluation is not included in the medical curriculum. For exam-
ple, Teerawattananon and Russell [25] reported a similar situa-
tion in Thailand.
Decision-making criteria
Respondents were asked what information they believe to be
relevant to the JRDL and how these should be weighed against
each other in the decision-making process. All respondents
considered safety, clinical effectiveness, and cost-effectiveness
as important when deciding on drug selection. The JRDL addi-
tion and deletion form offers a somewhat similar set of criteria
with stipulated requirements including evidence on safety,
clinical effectiveness, and cost information of the drug but not
cost-effectiveness (see Table 1). In other words, there was no
ormal requirement that cost-effectiveness information be sub-
itted as part of the process for deciding on the inclusion of
ew technologies on the JRDL. Both decision makers and aca-
emics asserted the nonuse of economic evidence in the selec-
ion of drugs for the JRDL, confirming that it is still not influen-
ial in formulary decisions. A recent review of the terms of
eference required the current JRDL committee to have a
hamacoeconomist on its board [18], although respondents
ere not very clear on this person’s role in the decision-making
rocess. One committee member proposed that the role of the
harmacoeconomist is to assess the quality of the economic
ata.
Since we don’t have enough knowledge or experience and there
are, you know, concerns over bias, we send the information to
the pharmacoeconomist to give us his opinion. (Decision Maker
Interviewee 5)
As a result of shortages in independent economic evaluations,
many of the economic evaluations available to decision makers awere prepared by manufacturers of technologies and this was
considered as reducing the likelihood of rigor and balance in the
reporting of results.
Political influence
The process described in the instructions for drug selection im-
plies that multiple criteria are used to reach a decision, although
the importance attached to each is not clear. In reality, respon-
dents pointed out that factors other than those explicitly men-
tioned often influence final decisions. For example, respondents
cited professional experience and personal opinion of clinicians
on the committee as primary factors in selecting drugs for the
formulary. Interview responses revealed a shared frustration over
this lack of clarity and consistency of decision-making criteria,
which, most interviewees suggested, enabled powerful influences
to shape the final decision. Priority setting in health care is con-
sistently described as a political process. Most respondents in this
study acknowledged this observation as they expressed their con-
cerns over covert influences on the decision-making process. For
example, the dominance of clinicians was a theme that persis-
tently featured in interviews with nonmedics.
People involved in making the decisions are those who are most
powerful. (Decision Maker Interviewee 2)
There has been a reevaluation of all terms of references of all com-
mittees. But I don’t expect doctors to stop using their personal judg-
ments, as they think they know best and they will always be the
majority. I think there must be legislation otherwise things will not
change. (Academic Interviewee 1)
There are a number of indicators for this dominance that have
been pointed out; the minister of health and most senior manag-
ers are in most cases clinicians, the perceived powerful influence
of the Jordan Medical Association (JMA) over policies related to
clinical audit and regulation of themedical practice, and the num-
ber of clinicians on the drug selection committee compared with
other professions. The implication of this for the use of economic
evaluation was considered to be that clinicians are more likely to
resist its formal use for two reasons. First, clinicians often see
efficiency and quality as conflicting principles. This can also be
linked to the “silomentality” of clinicianswho are often concerned
with best interests of their patients rather than the wider society
[6]. The second suggested reason was clinicians’ fear of power
shifting toward economists.
If we assume good intentions, clinicians want their patients to be
comfortable and to get best results in the shortest time. They be-
lieve that can only be attained by using the latest and most expen-
sive treatments. (Decision Maker Interviewee 6)
Clinicians feel that if the use of economic evaluation is legislated
their position will be affected. (Decision Maker Interviewee 5)
TheMedical Liability Law,which at the time of the studywas being
negotiated between the Ministry of Health and the JMA, wasmen-
tioned as an example of the influence of clinicians on policymak-
ing. The law is part of health reforms to improve the quality of care
in Jordan [29] and has been discussed for several years but so far
as not been finalized. JMA’s position from the law is that it should
rotect both citizens and clinicians and not put clinicians at risk of
egal action without solid evidence. At the same time, the JMA has
onsistently confirmed its commitment to improving standards of
are through monitoring medical practice and ensuring adher-
nce to international standards. Some interviewees saw this as an
pportunity for economic evaluation to gain acceptance among
linicians and the JMA to prove their commitment to best practice
nd higher standards of care.
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andwith the new law therewill bemore. Now the associationmain-
tains that they are committed to international standards. So if they
want to put their words into action theywould accept the economic
evidence as part of the evidence-based practice. (Academic Inter-
viewee 2)
Similar concerns were expressed over the influence of pharma-
ceutical companies on decision making at the national policy-
making level. For example, it was suggested that policymakers
and senior officials take considerable account of the interests of
pharmaceutical companies in decisions that might affect their in-
terests. Respondents also mentioned lobbying by drug companies
against policies that might have a negative impact on their com-
mercial performance.
Senior officials are convinced [of the benefits of using economic
evaluation], but there is lobbying from some parties who have spe-
cial interests and it ismainly the drug companies and the clinicians.
(Academic Interviewee 1)
Wehave to take that [drug companies’ interests] into consideration.
These companies are a big economic force and employ a lot of peo-
ple. If we want to use economic evaluation, it should not be seen as
in conflict with their interests. (Decision Maker Interviewee 2)
Furthermore, there was a concern among respondents around the
potential power of drug companies in influencing decisions if the
use of cost-effectiveness becomes an obligatory criterion. The in-
fluence of pharmaceutical companies can currently be seen in
their attempts to promote their products within the clinical com-
munity. New regulations for marketing campaigns by drug com-
panies, however, are being established and are expected to en-
hance the transparency of medicine promotion [16]. Respondents
suggested that the commissioning of independent studies where
possible and affordable and greater assessment and scrutiny of
industry-sponsored submissions by independent experts could
help reduce the drug companies’ influence.
Discussion and recommendations
This exploratory study is the first to address the use of economic
evaluation in Jordan in decisions related to national-level priority
setting. It notes the low current levels of usage of economic eval-
uation by the JRDL and identifies a number of reasons why this
might be the case. Participants consisted of a small yet diverse
sample of stakeholders. Many of those solicited, however, opted
not to take part in the study. As such, making wide-ranging con-
clusions about the research outcomes would be inappropriate.
The usefulness of the research findings, however, can be seen in
the helpful insights they provide into the decision-making envi-
ronment in Jordan, as well as in highlighting areas for future in-
vestigation.
The JRDL is unusual among national formulary bodies in that it
appears to apply little or no cost-effectiveness analysis to its deci-
sionmaking. In a developing country context, however, this is less
unusual [20]. The study suggests that the accessibility of economic
evaluation in Jordan is hindered by low levels of capacity to pro-
duce such analysis and understanding of the concepts involved.
Further barriers include the scarcity of skilled researchers and an-
alytical expertise, incomplete data, and insufficient financial re-
sources to commission studies. Training on economic evaluation
methods and required research skills is an area in clear need of
development. Limited resources and consequent reliance on ex-
ternal sources of analysis raise concerns about how topics are
selected and analyzed. Yothasamut et al. [7] found that in Thai-
land this distribution reflected the interests of international orga-
nizations that fund the majority of economic studies rather than
focusing on major health problems. While this can be understood
in light of limited resources, it should not work against, ormargin-
alize, national health priorities.Although the study revealed low levels of knowledge and un-
derstanding of economic evaluation, it revealed a supportive con-
text for developing its use. This was evident in the positive atti-
tudes indicated by decision makers and their interest in
enhancing their own knowledge and expertise. This support, how-
ever, should be considered with caution because previous re-
search suggests that the acceptability of economic evaluation is
sometimes inversely correlated to the recognition of its limita-
tions [25]. In this regard, it is interesting to note that some of the
barriers repeatedly cited in previous studies have not been indi-
cated in the interviews with Jordanian respondents. Ethical objec-
tions to economic evaluation, for example, formmuch of the crit-
icism to its utilitarian approach. As many analysts contend,
priority setting in health care tends to reflect othermoral concerns
such as equity, “rule of rescue,” and other societal values [25,30].
Similarly, implementation considerations and prohibitive up-
front costs of new technologies [6,20] were not discussed during
interviews. However, this may reflect the fact that the insufficient
usage of economic evaluation had meant that these further barri-
ers relating to ethics and implementation had yet to be encoun-
tered [31,32].
On the other hand, the results of this study are consistent with
findings of previous studies with respect to a number of accept-
ability barriers including fixed budgets, lack of incentives, and am-
biguity of decision-making roles and criteria [6,33]. Although these
barriersmaymanifest themselves differently in different systems,
they remain common across almost all those subjected to re-
search of this kind. This would imply that wider system reform—
including, for example, the trend toward the decentralization of
national systems in both developing and developed countries—
will not in itself remove impediments relating to financial struc-
tures, incentive systems, and lack of clarity over decision-making
roles and responsibilities. As well as these familiar barriers, two
further factors were identified in this study that could have signif-
icant implications for introducing the use of economic evaluation
in Jordan. The first is the dominance of the medical profession
over policy making. This situation is not unique to Jordan as clin-
ical discretion exists in all health care systems. The extent of in-
fluence over priority setting, however, varies and in Jordan is likely
to constitute a major obstacle if clinicians continue to associate
the introduction of economic criteria into decision making as a
threat to their autonomy and influence. On the other hand, it
might offer an opportunity if doctors can be convinced of the ben-
efits of an economic approach, and to appreciate the correlation
between clinical and cost-effectiveness of health technologies [6].
Added to this is pressure on the JMA to strengthen themonitoring
of quality standards.
The second striking feature of this study is the influence of
pharmaceutical companies on decision making at the national
level. The influence of highly organized interest groups such as
medical associations and pharmaceutical manufacturers has
long been reported [34], and there are well-documented ac-
counts of such groups challenging reforms that threaten their
interests or are perceived to undermine their power. For exam-
ple, Kwon [35] reports on how Korean doctors succeeded in re-
versing significant elements of pharmaceutical policy reforms
targeted toward inefficient prescribing behavior through na-
tionwide strikes that paralyzed the health system. Reich [34]
also reports the challenges faced by policymakers in developing
countries from clinical and commercial interest groups when
attempting to introduce cost-effectiveness criteria in drug se-
lection for national formularies. Consequently, policy analysts
argue that radical reforms are more likely to face strong oppo-
sition and counteractions by such groups. Analysts have there-
fore proposed an incremental approach to policy change that
involves deliberation with key stakeholders to secure their sup-
port [34,36].
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of recommendations. These can be categorized according to the
accessibility/acceptability framework introduced earlier in the
article [9]. In relation to accessibility, the study confirms that
training for researchers on economic evaluation techniques and
for decision makers on the interpretation and use of economic
data is required if incorporating economic evaluation is to be
formalized. Furthermore, limitations of the technical analysis
should be communicated to decision makers to enable them to
make informed decisions on the appropriate use of economic
evaluation. Finally, researcher and decision-maker exposure to
other countries’ experience in this arena can facilitate learning
and help avoid common pitfalls. However, prescriptions for im-
proving technology coverage decision making should not be
confined purely to considerations of accessibility. Although the
emphasis on increasing skills and resources would seem to re-
flect the findings of this study, further barriers are likely to
emerge as these aspects are addressed. For example, there is
likely to be a need for greater understanding of the structures
and governance of the health care system to establish the ex-
tent of compatibility with an economic evaluation–informed
approach. It is unclear from the study whether cost-effective-
ness analysis reflects the system characteristics of Jordan and
other developing country health care systems. What is clear is
that if analyses do not accurately reflect the decision-making
and implementation context, they will be of limited value [9].
imilarly, with regard to ethical considerations, it is also un-
lear to what extent the utilitarian precepts of cost-effective-
ess analysis are compatible with the wider social values of
ordanian society. To avoid repeating the oversimplistic pre-
criptions put forward for increasing the use of cost-effective-
ess analysis in developed country systems, we recommend
hat these aspects of acceptability be addressed in future re-
earch initiatives. Finally, there is a need for a reevaluation of
ecision-making processes themselves including via the JRDL.
he current process lacks transparency and appears to be dis-
roportionately influenced by political interests, which com-
romises accountability and fairness in priority setting.
Source of financial support: No funding was received to sup-
ort research or development of manuscript.
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